KSI-101
Macular Edema Secondary to Inflammation (MESI)
Phase 1bAPEX Data Presented; PEAK & PINNACLE Actively Recruiting
Key Facts
Indication
Macular Edema Secondary to Inflammation (MESI)
Phase
Phase 1b
Status
APEX Data Presented; PEAK & PINNACLE Actively Recruiting
Company
About Kodiak Sciences
Kodiak Sciences is a public biopharma company singularly focused on developing and commercializing novel, durable treatments for the leading causes of blindness. Its core innovation is the ABCD platform, which conjugates antibodies to a proprietary phosphorylcholine-based biopolymer to extend ocular half-life and enable high drug-antibody ratios for multi-mechanistic therapies. The company has advanced its lead asset, tarcocimab, through multiple Phase 3 trials, built a commercial-scale manufacturing facility, and is expanding its pipeline with bispecific candidates like KSI-501 and KSI-101.
View full company profile